The effect of bromocriptine withdrawal after long-term treatment on prolactin levels has been investigated in thirty-seven patients with prolactinomas. In ten patients with macroprolactinomas and post-operatively excessively high prolactin levels persisting suppression of prolactin secretion after bromocriptine withdrawal has been observed. This 
not observed in patients with microprolactinomas or macroprolactinomas with only moderately elevated prolactin levels. The degree of persisting suppression correlated to the height of prolactin levels before treatment and to the duration of bromocriptine therapy. No correlation was found between the rise of prolactin levels after bromocriptine withdrawal and withdrawal time. It is suggested that the persisting suppression of prolactin levels is a sequence of reduction in tumour size. This anti-proliferative action of bromocriptine seems to be specific for the prolactin secreting cells in macroprolactinomas with high proliferation rate and high prolactin turn-over. These findings offer new possibilities in the management of patients with macroprolactinomas.
The beneficial effects of bromocriptine (BC) treatment in hyperprolactinaemic states has been widely documented in recent years (Thorner 1977) . Post-partum hyperprolactinaemia (Brun del Re et al. 1973 ) and non-puerperal amenorrhoeagalactorrhoea-syndromes associated with hyperprolactinaemia (del Pozo et al. 1974 ) are treated effectively with BC. The efficacy of this ergot-alkaloid derivative has also been proven in patients with prolactin (PRL) secreting pituitary adenomas, leading to normal ovulatory cycles and pregnancies (Bergh et al. 1978; and normalisation of hyperprolactinaemic hypogonadism in the male (Carter el al. 1978) .
Inhibition of PRL secretion by ergot-alkaloids is mediated by a central effect on the hypothalamus and by a direct action on the PRL-secreting pituitary cell (Lu et al. 1971; Wuttke et al. 1971) . In addition to the inhibition of PRL secretion reduction in adenoma size of transplanted pituitary tumours in rats was found after treatment with ergot-derivatives (Quadri et al. 1972; MacLeod 8c Lehmeyer 1973) . In addition several case reports have supported the idea that BC has also an anti-proliferative effect on pituitary adenoma growth in man. Shrinking of the prolactinoma in these patients was concluded by nor¬ malisation of visual fields (Corenblum et al. 1975; Vaidya et al. 1977; Friesen 8c Tolis 1977; , by changes of the osseous structure of the sella turcica (Sobrinho et al. 1978) (Chiodini et al. 1978) have been reported.
The following study was designed to investigate the described anti-proli¬ ferative effect on prolactinoma growth in different groups of hyperprolactinae¬ mic patients by measuring PRL levels before, during and after withdrawal of long-term BC treatment.
PATIENTS
Thirty-seven patients with prolactinomas, twenty-one females and sixteen males were divided into two groups according to the X-ray configuration of the sella turcica and to the height of PRL levels: In patients with microprolactinomas, i.e. minute changes of the sellar floor (Vezina Sc Sutton ¡974) and PRL levels below 5000 /<U/ml and in patients with inacroprolactinomas with an enlarged sella turcica and PRL levels above 5000 /(U/ml. All 
RESULTS
Microprolactinomas.
Under BC treatment PRL levels could be normalised in six patients (Table 1) . After BC withdrawal PRL levels increased again to 61.9 ± 6.7°/o of the PRL levels before therapy ( Prolactin levels in female patients with macroprolactinomas before, during (-), and after withdrawal (-) of bromocriptine treatment. Dosage of bromocriptine (mg/d) is shown by the hatched bars at the top of each panel.
creased to 52.3 ± 7.7 % of the pre-treatment level (Table 4 ). In five patients (pat. 1-5; Table 2 ) with excessively high PRL levels before BC therapy PRL increased only up to 42.6 ± 9.0°/o of the basal level (Fig. 1) . In four patients with signi¬ ficantly lower pre-treatment levels (pat. 6-9; (Table 4) : 1) microprolactinomas (n = 8), 2) macroprolactinomas with persisting suppression of PRL levels below 50°/o of pre-treatment levels (n=10), 3) macroprolactinomas without significantly different PRL levels after BC with¬ drawal compared to pre-treatment ( = 8), and 4) macroprolactinomas after additional radiotherapy (n=ll). No significant correlation in patients with microprolactinomas was found between the above mentioned parameters. In patients with macroprolactinomas who responded with a persisting lowering of PRL levels a significantly positive correlation between the PRL decrease after withdrawal and decrease during therapy (P < 0.05) and a significantly negative correlation between the increase and duration of therapy (P < 0.001) was found. However no correlation existed between the increase of PRL levels and duration of BC withdrawal. In macroprolactinomas with PRL levels after withdrawal not significantly different from pre-treatment levels no correlation could be shown for the respective parameters. No significant correlation between PRL increase after BC withdrawal, decrease during therapy and duration of therapy was found in patients having received additional radio¬ therapy.
DISCUSSION
In rats, ergot alkaloids were shown to cause reduction of tumour size in trans¬ planted pituitary adenomas (Quadri et al. 1972; MacLeod 8c Lehmeyer 1973; Lloyd et al. 1975 ). Several mechanisms may explain this antiproliferative effect. Increased PRL concentration in the lactotroph after inhibition of its secretion may cause reduced PRL synthesis by an intracellular negative feed-back mechanism . Direct inhibition of DNA-synthesis (Davies et al. 1974 ) and inhibition of enzymatic activity (Nagy 8c MacLeod 1979) was found after BC treatment. Since 3'-5'-cyclic-AMP is also implicated in stimula¬ ting PRL secretion Fig. 1 and 2 ; Table 4 ). Histological examination of these adenomas shows increased mitotic rates and signs of enhanced proliferation (Peillon et al. 1978) . This may explain the efficacy of BC particularly in these adenomas. Our findings are supported by other case reports of patients with large pituitary adenomas and high PRL levels ranging from 12 000 to 78 000 //U/ml. In these patients reduction of adenoma size after BC treatment could be documented by X-ray, operation, and computer tomography (Corenblum et al. 1975; Vaidya et al. 1977; Nillius et al. 1978; McGregor el al. 1979) , also accompanied by a striking decrease of PRL levels and persisting suppression of PRL secretion after withdrawal (Sobrinho et al. 1978; von Werder et al., in press).
In contrast to the patients with macroprolactinomas and high PRL levels persisting suppression of PRL secretion was not observed in patients with only moderately elevated PRL levels. Particularly in microprolactinomas ( 
